Costs of Treatment of Severe COPD Exacerbation in Serbia
References
- 1. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V. et al. (2012). Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 380(9859), 2095-2128. DOI: 10.1016/S0140-6736(12)61728-0.
- 2. Mathers CD, Loncar D. (2006). Projections of Global Mortality and Burden of Disease from 2002 to 2030. Plos Medicine. 3(11), 2011-2030. DOI:10.1371/journal. pmed.0030442
- 3. Blasi F, Cesana G, Conti S, Chiodini V, Aliberti S, Fornari C & Mantovani LG. (2014). The clinical and economic impact of exacerbations of chronic obstructive pulmonary disease: a cohort of hospitalized patients. PLoS One. 9(6), 1-8. DOI:10.1371/journal.pone.0101228
- 4. Wan E, DeMeo D, Hersh C, Shapiro S, Rosiello R, Sama S, Fuhlbrigge A, Foreman M & Silverman E. (2011). Clinical predictors of frequent exacerbations in subjects with 6 severe chronic obstructive pulmonary disease (COPD). Respir Med. 105(4), 588–594. DOI: 10.1016/j.rmed.2010.11.015
- 5. Hurst J, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, Calverley P, Rennard S, Wouters EF & Wedzicha JA. (2010). Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease. N Engl J Med. 363(12), 1128-1138. DOI:10.1056/NEJMoa0909883.
- 6. Parikh R, Shah TG & Tandon R. (2016). COPD exacerbation care bundle improves standard of care, length of stay, and readmission rates. Int J Chron Obstruct Pulmon Dis. 11(1), 577-583. DOI: 10.2147/COPD.S100401.
- 7. Montserrat-Capdevila J, Godoy P, Marsal JR, Barbé F & Galvn L. (2015). Risk of exacerbation in chronic obstructive pulmonary disease: a primary care retrospective cohort study. BMC Fam Pract. 16:173. DOI: 10.1186/s12875-015-0387-6
- 8. Guarascio AJ, Ray SM, Finch CK & Self TH. (2013). The clinical and economic burden of chronic obstructive pulmonary disease in the USA. Clinicoecon Outcomes Res. 5, 235-245. DOI: 10.2147/CEOR.S34321
- 9. Lazic Z, Gajovic O, Tanaskovic I, Milovanovic D, Atanasijevic D & Jakovljevic M. (2012). GOLD Stage Impact on COPD Direct Medical Costs in the Elderly. Health Behav & Pub Health. 2(3), 1-7.
- 10. Menn P, Leidl R & Holle R. (2012). A lifetime Markov model for the economic evaluation of chronic obstructive pulmonary disease. Pharmacoeconomics. 30(9), 825-840. DOI: 10.2165/11591340-000000000-00000
- 11. Hoogendoorn M, Kappelhoff BS, Overbeek JA, Wouters EF & Rutten-van Mölken MP. (2012). Which long-acting bronchodilator is most cost-effective for the treatment of COPD? Neth J Med. Review. 70(8), 357-364.
- 12. Ornek T, Tor M, Altın R, Atalay F, Geredeli E, Soylu O & Erboy F. (2012). Clinical factors affecting the direct cost of patients hospitalized with acute exacerbation of chronic obstructive pulmonary disease. Int J Med Sci. 9(4), 285-90. DOI: 10.7150/ijms.4039
- 13. Yu AP, Yang H, Wu EQ, Setyawan J, Mocarski M & Blum S. (2011). Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysis. J Med Econ. 14(3), 315-323. DOI: 10.3111/13696998.2011.576295.
- 14. Abudagga A, Sun SX, Tan H & Solem CT. (2013). Exacerbations among chronic bronchitis patients treated with maintenance medications from a US managed care population: an administrative claims data analysis. Int J Chron Obstruct Pulmon Dis. 8, 175-85. DOI: 10.2147/COPD.S40437.
- 15. Global Initiative for Chronic Obstructive Lung Disease. (2014). Global Strategy for the Diagnosis. Management and Prevention of Chronic Obstructive Pulmonary Disease. Available on: http://www.goldcopd.org
- 16. World Health Organization. Chronic obstructive pulmonary disease (COPD).(2011). Available on: http://www.who.int/respiratory/copd/en/
- 17. Valente S, Pasciuto G, Bernabei R & Corbo GM. (2010). Do we need different treatments for very elderly COPD patients? Respiration. 80(5), 357–368. DOI: 10.1159/000320221.
- 18. Hillas G, Perlikos F, Tsiligianni I & Tzanakis N. (2015). Managing comorbidities in COPD. Int J Chron Obstruct Pulmon Dis. 10, 95-109. DOI: 10.2147/COPD. S54473.
- 19. Pasquale MK, Sun SX, Song F, Hartnett HJ & Stem-kowski SA. (2012). Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly Medicare population. Int J Chron Obstruct Pulmon Dis. 7, 757-764. DOI: 10.2147/COPD.S36997.
- 20. Doos L, Uttley J, Onyia I, Iqbal Z, Jones PW & Kadam UT. (2014). Mosaic segmentation, COPD and CHF multimorbidity and hospital admission costs: a clinical linkage study. J Public Health (Oxf). 36(2), 317-324. DOI: 10.1093/pubmed/fdt070.
- 21. Halpin DM & Miravitlles M. (2006). Chronic obstructive pulmonary disease: the disease and its burden to society. Proc Am Thorac Soc. 3(7), 619–623. DOI: 10.1513/pats.200603-093SS
- 22. Mapel DW, Hurley JS, Frost FJ, Petersen HV, Picchi MA & Coultas DB. (2000). Health care utilization in chronic obstructive pulmonary disease. A case-control study in a health maintenance organization. Arch Intern Med. 160(17), 2653–2658. DOI:10.1001/archinte.160.17.2653
- 23. Cazzola M, Bettoncelli G, Sessa E, Cricelli C & Biscione G. (2010). Prevalence of comorbidities in patients with chronic obstructive pulmonary disease. Respiration. 80(2), 112–119. DOI: 10.1159/000281880
- 24. Mannino DM1, Watt G, Hole D, Gillis C, Hart C, Mc-Connachie A, Davey Smith G, Upton M, Hawthorne V, Sin DD, Man SF, Van Eeden S, Mapel DW & Vestbo J. (2006). The natural history of chronic obstructive pulmonary disease. Eur Respir J. 27(3), 627–643. DOI: 10.1183/09031936.06.00024605
- 25. Säynäjäkangas O, Kinnunen T, Tuuponen T & Keistinen T. (2004). Length of stay and interval to readmission in emergency hospital treatment of COPD. Age Ageing. 33(6), 567-570. DOI: 10.1093/ageing/afh188
- 26. Harries TH, Thornton HV, Crichton S, Schofield P, Gilkes A & White PT. (2015). Length of stay of COPD hospital admissions between 2006 and 2010: a retrospective longitudinal study. Int J Chron Obstruct Pulmon Dis. 10, 603-611. DOI: 10.2147/COPD. S77092.
- 27. Diamantea F, Kostikas K, Bartziokas K, Karakontaki F, Tsikrika S, Pouriki S, Polychronopoulos V, Karagiannidis N, Haniotou A & Papaioannou A. (2014). Prediction of hospitalization stay in COPD exacerbations: the AECOPD-F score. Respir Care. 59(11), 1679-1686. DOI: 10.4187/respcare.03171.
- 28. Hertel N, Kotchie RW, Samyshkin Y, Radford M, Humphreys S & Jameson K. (2012). Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis. Int J Chron Obstruct Pulmon Dis. 7, 183-199. DOI: 10.2147/COPD.S29820.
Language: English
Page range: 51 - 58
Submitted on: Dec 28, 2017
Accepted on: Feb 17, 2018
Published on: Jun 5, 2020
Published by: Sciendo
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year
Keywords:
Related subjects:
© 2020 Radisa Pavlovic, Svetlana Stojkov, Zahida Binakaj, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.